UNH (US)


November 30, 2025

Home Health: CY26 Medicare Cuts Softened; CY27+ Still Points to Small YoY Declines [PNTG, EHAB, BTSG, ADUS, AVAH, UNH]

By Beth Steindecker

Home health (HH) agencies [PNTG, EHAB, BTSG, ADUS, AVAH, UNH] received meaningful relief in Friday’s final CY26 Medicare HH reimbursement rule, which pares back the proposed aggregate spending cut and rate discounts. However, CMS signals…

Read More >>

November 26, 2025

Medicare Advantage Tech Changes Proposal: RFI Eases Risk Adjustment Concerns, Star Rating Changes Afoot [HUM, ALHC, UNH, CVS, ELV, PRVA, ASTH]

By Beth Steindecker

Our read of the proposed Contract Year 2027 Policy and Technical Changes regulation for Medicare Advantage (MA) and Part D (fact sheet here), confirms our expectations for a positive regulatory backdrop for 2027 for MA [HUM, ALHC,…

Read More >>

November 23, 2025

ASC Wins in Final CMS Rate Rule, Slight Hospital Wins but Lingering Concerns

By Beth Steindecker

Ambulatory surgery centers (ASCs) [SGRY, AmSurg, THC, HCA, UNH] secured some policy wins in the final CY26 Medicare outpatient prospective payment system (OPPS) rule, consistent with the July proposal (notably a broadened covered procedure list,…

Read More >>

November 19, 2025

Finance Committee Hearing: Still Think ACA Subsidy Deal is More Likely Even If Late [OSCR, CNC, CYH, UHS, DVA, FMS, HQY, WBS]

By Beth Steindecker

This morning’s Senate Finance Committee hearing on rising healthcare costs did little to break the stalemate on Obamacare, but no one expected a breakthrough today. The hearing primarily served as a venue for both sides…

Read More >>

November 9, 2025

Obamacare HIX Fix: HSAs for All or Compromise on Subsidy Changes? We Still Think the Latter [OSCR, CNC, ELV, MOH, UNH, HQY, WBS, EHTH]

By Beth Steindecker

President Trump’s Truth Social posts over the weekend, along with that of other Republicans, suggest an existential threat for Obamacare insurers [OSCR, CNC, ELV, MOH, UNH] and potentially other commercial health insurers [CI, CVS] while…

Read More >>

November 7, 2025

Obesity Drug Pricing Deal: Devil in the Details

By John Leppard

As outlined by the Trump administration, we view yesterday’s obesity drug pricing deal with NVO and LLY as a modest near-term positive (potentially better for LLY), with the $245 / mo. price point for Medicare…

Read More >>

November 5, 2025

Medicare Advantage: Still Expecting Light Regulatory Touch for CY27 [HUM, ALHC, AGL, UNH, CVS, ELV, CNC, PRVA]

By Beth Steindecker

Listening to recent earnings calls held by various Medicare Advantage (MA) insurers and value-based care providers [HUM, ALHC, AGL, UNH, CVS, ELV] leaves us with the following thoughts on the MA regulatory policy environment for…

Read More >>

October 15, 2025

PBMs: Policy Headwinds Persist with Some New Developments [CVS, CI, UNH, ELV]

By Beth Steindecker

Policy headwinds facing pharmacy benefit managers (PBMs) [CVS, CI, UNH, ELV] remain entrenched despite shifting details since this spring. Recent developments, like California’s PBM law, White House drug pricing efforts, and the FTC litigation, underscore…

Read More >>

October 14, 2025

[HUM] Stars Rating Litigation Likely Brings Chapter to Close

By Beth Steindecker

We think this morning’s court ruling against Humana (HUM) in its Medicare Advantage (MA) Stars litigation is likely the end of the road in its efforts to secure a higher score for its 2026 payment…

Read More >>

October 8, 2025

[EHAB, PNTG, ADUS, BTSG, UNH, AVAH]: Medicare Home Health Expectations

By Beth Steindecker

We remain optimistic that home health companies [EHAB, PNTG, ADUS, BTSG, UNH, AVAH] will secure some mitigation in the final CY26 Medicare reimbursement rule, which may be released as early as month’s end and as…

Read More >>